Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration.

ABSTRACT:

Background

The objective of this study is to describe the use of targeted therapies for the treatment of advanced renal cell carcinoma (RCC) and overall survival (OS) among patients in clinical practice in the Veterans Health Administration (VHA).

Methods

A retrospective cohort of 286 patients from 24 VHA Medical Centers diagnosed with advanced clear cell RCC between Fiscal Year (FY) 2010 and FY2014 was followed through September 30, 2016. Among patients who received targeted therapy, we described the medications taken, duration of therapy, and overall survival. We also assessed the effect of the first therapy received on overall survival using Cox Proportional Hazards models.

Results

There were 66 patients who did not receive therapy for their advanced RCC. Of the 22

SUBMITTER: Aspinall SL 

PROVIDER: S-EPMC6825975 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature